South Korea-based IMM Private Equity plans to acquire Kolmar Korea Holdings’ pharmaceutical contract manufacturing organisation and its drug development business for $413 million (KRW512.4 million), according to media reports.
Kolmar Korea said that its toothpaste business, which is part of its pharmaceutical business unit, will not be included in the sale, according to the company’s filing, AVCJ reported.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
